Manufactured CAR T cells ready for infusion into a patient

FDA approves BCMA-targeted CAR T-cell therapy for multiple myeloma

Apr 15, 2021

The Food and Drug Administration approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that has not responded to or has returned after at least four different prior cancer treatments. The approval is based, in part, on earlier clinical work led by James N. Kochenderfer, M.D., Senior Investigator in the Surgery Branch. Read more...

Dr. Brigitte Widemann

Brigitte Widemann named a Top Ten Clinical Research Achievement Awardee

Mar 31, 2021

Brigitte C. Widemann, M.D., Chief of the Pediatric Oncology Branch, has been named a Top Ten Clinical Research Achievement Awardee by the Clinical Research Forum, and she was awarded a Distinguished Clinical Research Achievement Award for her study “Selumetinib in Children with Inoperable Plexiform Neurofibromas.” Read more...

Respiratory System Anatomy

FDA grants orphan drug designation to PRGN-2012 for recurrent respiratory papillomatosis

Mar 30, 2021

The Food and Drug Administration has granted orphan drug designation to PRGN-2012 immunotherapy for use in patients with recurrent respiratory papillomatosis. Read more...

High magnification micrograph of a clear cell renal cell carcinoma

Combination therapy in patients with advanced kidney cancer found to be highly effective

Mar 26, 2021

A phase III international clinical trial that tested the combination therapy of nivolumab and cabozantinib in patients with advanced, untreated renal-cell carcinoma yielded promising results. Read more...

HPV-16 E5 Oncoprotein

Clinical trial investigates vaccine to treat recurrent respiratory papillomatosis after surgery

Mar 24, 2021

Scott M. Norberg, D.O., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a study of PRGN-2012, an experimental therapeutic vaccine for adults with recurrent respiratory papillomatosis (RRP). RRP is a rare disorder caused by human papillomavirus. Read more...

mouse model of human colorectal cancer

New trial evaluates immunotherapy combinations in adults with advanced small bowel and colorectal cancers

Mar 15, 2021

Julius Strauss, M.D., Assistant Research Physician in the Laboratory of Tumor Immunology and Biology, is leading a clinical trial evaluating a combination of immunotherapy drugs to see if they can shrink advanced tumors of the small bowel, colon and rectum. Read more...

Human Natural Killer Cell

Clinical trial evaluates combination therapy for men with metastatic prostate cancer

Mar 11, 2021

Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is leading a study of an experimental treatment for men with two types of prostate cancer: one type that responds to hormone therapy and one that doesn’t.Read more...

anatomy of thymus gland

Clinical trial studies immunotherapy combination for recurrent thymoma and thymic carcinoma

Feb 9, 2021

Thymic epithelial tumors (TETs) are rare cancers that originate from the cells of the thymus, a small organ that sits in the chest between the lungs and above the heart. Arun Rajan, M.D., Senior Clinician in the Thoracic and GI Malignancies Branch, is leading a clinical trial of a therapy for thymoma and thymic carcinoma that has returned after chemotherapy and cannot be treated with surgery. Read more...

skin biopsy

Clinical trial studies therapy for relapsed/refractory T-cell malignancies

Jan 5, 2021

Milos Miljkovic, M.D., M.Sc., Assistant Research Physician in the Lymphoid Malignancies Branch, is leading a study of a 4-drug combination treatment strategy using romidepsin, oral 5-azacitidine, dexamethasone and lenalidomide for T-cell malignancies (TCMs). Researchers are seeking to determine the safety, side effects, and best dose of this 4-drug combination for people with relapsed/refractory TCM.  Read more...

harvested GIST tissue

Study evaluates, treats, and follows patients with gastrointestinal stromal tumors

Dec 31, 2020

More than half of all gastrointestinal stromal tumors (GISTs) start in the stomach, but they can start anywhere in the GI tract. Andrew M. Blakely, M.D., Assistant Research Physician in the Surgical Oncology Program, is leading a study of GIST that could benefit current and future patients. Read more...

Pages